Back to top
more

TherapeuticsMD (TXMD)

(Delayed Data from NSDQ)

$1.89 USD

1.89
5,719

0.00 (0.00%)

Updated Apr 18, 2024 03:57 PM ET

After-Market: $1.89 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for TXMD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

TherapeuticsMD, Inc. [TXMD]

Reports for Purchase

Showing records 1 - 20 ( 25 total )

Company: TherapeuticsMD, Inc.

Industry: Medical - Drugs

Record: 1

11/30/2022

Company Report

Pages: 4

Dropping Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: TherapeuticsMD, Inc.

Industry: Medical - Drugs

Record: 2

08/16/2022

Company Report

Pages: 5

Proof of Life; Annovera Gets Back Into Growth Mode

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: TherapeuticsMD, Inc.

Industry: Medical - Drugs

Record: 3

07/15/2022

Company Report

Pages: 3

Path Forward Not Clear As Acquisition by EW Terminated After Unsuccessful Tender; Rating & Price Target Under Review

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: TherapeuticsMD, Inc.

Industry: Medical - Drugs

Record: 4

06/07/2022

Company Report

Pages: 4

Downgrading to Neutral on Acquisition

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: TherapeuticsMD, Inc.

Industry: Medical - Drugs

Record: 5

05/17/2022

Company Report

Pages: 5

Questions Persist After 1Q Results; Price Target Down to $4 on Lowered Expectations

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: TherapeuticsMD, Inc.

Industry: Medical - Drugs

Record: 6

03/11/2022

Company Report

Pages: 5

Annovera Supply Issue Causes 4Q21 Miss but New Direction Makes for a Promising 2H22

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: TherapeuticsMD, Inc.

Industry: Medical - Drugs

Record: 7

03/08/2022

Daily Note

Pages: 3

vitaCare Divestiture Gives TherapeuticsMD a Much-Needed Shot in the Arm; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: TherapeuticsMD, Inc.

Industry: Medical - Drugs

Record: 8

11/12/2021

Company Report

Pages: 5

A New Day for TherapeuticsMD: Major Leadership and Strategic Changes Announced; Reiterate Buy, PT to $3

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: TherapeuticsMD, Inc.

Industry: Medical - Drugs

Record: 9

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for TXMD

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: TherapeuticsMD, Inc.

Industry: Medical - Drugs

Record: 10

08/05/2021

Company Report

Pages: 5

Respectable Growth in 2Q Expected to Continue Through 2H21 as Strategy Appears to be Paying Off

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: TherapeuticsMD, Inc.

Industry: Medical - Drugs

Record: 11

05/07/2021

Company Report

Pages: 5

Promising Trends But Portfolio Still Impacted by COVID-19; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: TherapeuticsMD, Inc.

Industry: Medical - Drugs

Record: 12

03/03/2021

Company Report

Pages: 5

4Q20 Revenue Beat and Stronger Balance Sheet Poise Portfolio for Growth in 2021; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: TherapeuticsMD, Inc.

Industry: Medical - Drugs

Record: 13

01/29/2021

Industry Report

Pages: 7

Takeaways From Our Coverage at the 2021 H.C. Wainwright BioConnect Conference

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: TherapeuticsMD, Inc.

Industry: Medical - Drugs

Record: 14

01/28/2021

Company Report

Pages: 4

Model Updates to Reflect Lower Revenues Due to Continued COVID-19 Overhang; Reiterate Buy, Lower PT to $4.

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: TherapeuticsMD, Inc.

Industry: Medical - Drugs

Record: 15

01/11/2021

Daily Note

Pages: 4

TherapeuticsMD Hits $20M Revenue Covenant for 4Q, Strong Growth for Annovera and Imvexxy Projected in 2021; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: TherapeuticsMD, Inc.

Industry: Medical - Drugs

Record: 16

11/10/2020

Company Report

Pages: 5

Earnings Beat in Encouraging Quarter Across Portfolio; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: TherapeuticsMD, Inc.

Industry: Medical - Drugs

Record: 17

09/28/2020

Daily Note

Pages: 3

Annovera Shows Momentum Which Should Bolster Confidence; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: WERTHER C

Price: 10.00

Research Provided by a Third Party

Company: TherapeuticsMD, Inc.

Industry: Medical - Drugs

Record: 18

08/07/2020

Company Report

Pages: 5

Annovera Becomes the Focus for Growth; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: TherapeuticsMD, Inc.

Industry: Medical - Drugs

Record: 19

05/07/2020

Company Report

Pages: 5

Annovera Moves to Forefront, We Expect Recovery of Momentum by Year-End; Reiterate Buy, Target Goes to $5

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: TherapeuticsMD, Inc.

Industry: Medical - Drugs

Record: 20

03/27/2020

Daily Note

Pages: 3

No Surprise as Guidance Is Pulled as Covid-19 Creates Uncertainty; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party